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Background:  The  iso-osmolar  contrast  agent  iodixanol  may  be associated  with  a lower  incidence  of  cardiac
events  than low-osmolar  contrast  media  (LOCM),  but  previous  trials  have  yielded  mixed  results.
Objective:  To compare  the risk of  total  cardiovascular  events  of  the  iso-osmolar  contrast  medium,  iodix-
anol,  to LOCM.
Methods:  Medical  literature  databases  were  searched  to  identify  comparisons  between  iodixanol  and
LOCM  with  cardiovascular  events  as  a primary  endpoint.  A  random-effects  model  was  used  to obtain
pooled  odds  ratio  (OR)  for within-hospital  and  30-day  events.
Results:  A  total  of 2 prospective  cross-sectional  studies  and 11  randomized  controlled  trials  (RCTs)  (cover-
ing 6859  subjects)  met  our criteria.  There  was  no  signiﬁcant  difference  in  the  incidence  of within-hospital
and  30-day  cardiovascular  events  when  iodixanol  was  compared  with  LOCM,  with  pooled  OR  of 0.72
(95%CI  0.49–1.06,  p = 0.09)  and  1.19  (95%CI  0.70–2.02,  p =  0.53),  respectively.  Subgroup  analysis  showed
no  relative  difference  when  iodixanol  was  compared  with  ioxaglate  (OR  = 0.92,  95%CI  0.50–1.70,  p  =  0.80)
and  iohexol  (OR  = 0.75,  95%CI  0.48–1.17,  p = 0.21).  However,  a  reduction  in  the  within-hospital  cardio-
vascular  events  was  observed  when  iodixanol  was  compared  with  LOCM  in  the  RCT  subgroup  (OR  = 0.65,
95%CI  0.44–0.96,  p =  0.03).  Sensitivity  analyses  revealed  that  three  studies  had  a strong  impact  on  the  asso-
ciation  of  within-hospital  cardiovascular  events  between  iodixanol  and  LOCM.  Meta-regression  analysis
failed  to account  for heterogeneity.  No publication  bias  was  detected.
Conclusions:  This  meta-analysis  demonstrates  that  there  is  no conclusive  evidence  that  iodixanol  is supe-
rior to LOCM  overall  with  regard  to fewer  cardiovascular  events.© 2014  Published  by  Elsevier  Ltd on  behalf  of  Japanese  College  of  Cardiology.
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ntroduction
The contribution of contrast media to major complications
uring coronary angiography or coronary angioplasty has been
ebated [1–3]. Compared with high osmolar contrast media
HOCM), nonionic low osmolar contrast media (LOCM) have been
hown to decrease the incidence of major complications associated
ith diagnostic cardiac catheterization [4].
Today we have a third category of contrast media, the non-
onic dimers, iodixanol with an osmolarity close to that of plasma.
n experimental studies, iodixanol induced only minor changes in
ardiac function [5]. In the ﬁrst comparative clinical studies with
odixanol, it was shown that iodixanol had generally no electro-
hysiological or hemodynamic effects, or these effects were less
ronounced when compared with the other contrast media [6].
ubsequent trials also demonstrated that iodixanol signiﬁcantly
ecreased the incidence of cardiac events in patients undergo-
ng coronary angiography when compared with different types of
OCM [7,8]. However, other investigations have given conﬂicting
esults and raised doubts about the usefulness of iodixanol [3,9]. In
iew of these differences, the objective of this meta-analysis was
o provide a comprehensive comparison of the risk of cardiovas-
ular events of the iso-osmolar agent iodixanol and the currently
vailable LOCM.
ethods
earches
MEDLINE, Embase, ISI Web  of Knowledge, Google Scholar, clin-
cal trials.gov, and international conference abstracts (from 1980
ntil April 30, 2013) were searched using the medical subject head-
ngs (MeSH) “iso-osmolar,” “iodixanol,” “low-osmolar,” “iohexol,”
iopamidol,” “iopromide,” “iomeprol,” and “cardiovascular dis-
ase.” The reference lists of pertinent articles were also reviewed.
election
We  performed initial screening of study titles or abstracts,
hile the second screening was based on full-text review. A study
as included if it randomized patients undergoing contrast media
pplication to either LOCM or iodixanol, and if data on cardiac
vents were routinely ascertained in all patients. The search was
erformed without any language restrictions but was  limited to
uman subjects. When an abstract from a meeting and a full report
eferred to the same study, only the full report was  included in
he analysis. When multiple reports were available from the same
tudy, we used the most complete and/or recently reported data.eﬁnition of cardiovascular disease events
Cardiovascular disease events were deﬁned as a composite of
eath, stroke, myocardial infarction (MI), angina pectoris, new . . . . .  .  . . . . . . .  . . . . .  .  . . . . . . . .  .  . . .  . . .  . . . . . . .  . . .  .  .  . . . .  .  . . .  .  .  .  . . . .  . . .  . . .  .  . . . . . 267
arrhythmias, congestive heart failure, and emergent need for revas-
cularization.
Data extraction
Two  independent investigators (Zhang and Wu)  reviewed each
report to determine its eligibility and then extracted and tabulated
all of the relevant data. Disagreement was  resolved by consensus
between the two authors. The following information was obtained
from each article: ﬁrst author, year of publication, total number
of patients, mean age, average contrast volume, information about
sex, diabetes, and type of LOCM used.
Statistical analysis
The primary end point was the incidence of total cardiac events
as deﬁned by each individual study protocol. Data from all the
selected studies were combined to estimate the pooled odds ratio
(OR) for iodixanol versus LOCM using a random-effects model.
Signiﬁcant between-study heterogeneity was  expected regarding
study populations and because different LOCM were used as com-
parators; therefore, a random-effects model was used to produce
across-study summary OR with 95% conﬁdence intervals (CI). The
Cochrane x2 test and the I2 test were used to evaluate heterogeneity
among studies, with a threshold value of p = 0.10 being considered
signiﬁcant [10]. To investigate the dynamic trend of the associa-
tion, cumulative meta-analysis was performed by assortment of
publication times [11]. Publication bias was  evaluated by creating
a funnel plot of each study’s effect size versus the SE. Funnel plot
asymmetry was  assessed by Begg’s test and Egger’s test.
Meta-regression analyses were performed to explore sources
of heterogeneity. Variables such as total number of patients, mean
age, and average contrast volume were examined to detect any sig-
niﬁcant inﬂuence on the risk of total cardiovascular disease events.
To assess the effect of individual studies on the summary esti-
mate of effect, we  performed an inﬂuence analysis, in which the
pooled estimates were recalculated by omitting 1 study at a time.
All statistical tests were performed with the STATA software, ver-
sion 11.0 (Stata Corporation, College Station, TX, USA) and Review
Manager 5.0.4 software (available from The Cochrane Collaboration
at http://www.cochrane.org). A value of p < 0.05 was  considered
statistically signiﬁcant.
Results
Search results
Fig. 1 shows a ﬂow diagram of study selection. We  identiﬁed
a total of 213 citations. Of these citations, 166 were excluded
by reviewing the title and abstract, leaving 47 studies for fur-
ther evaluation. After full-text evaluation, 34 of these 47 studies
were excluded. Most of the excluded studies did not contain perti-
nent data. A total of 13 studies [1–3,7–9,12–18] that covered 6859
262 B.-C. Zhang et al. / Journal of Cardiology 63 (2014) 260–268
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atients [3416 (49.8%) in the iodixanol group and 3443 (50.2%) in
he LOCM group] eventually fulﬁlled our inclusion criteria and were
sed in this meta-analysis.
tudy characteristics
A total of 13 investigations were reported in the 2 prospective
ross-sectional studies [2,3] and 11 randomized controlled trials
RCTs) [1,7–9,12–18]. The study quality was generally excellent for
he RCTs included, overall, two trials had a Jadad score of 5, ﬁve
cored 4, two scored 3, and the remaining two scored 2. Table 1
hows their characteristics. The studies were published between
993 and 2012. The size of the study population ranged from 74
o 1411 patients. Patients received different formulations of con-
rast media. The 2770 iodixanol patients were given either the
70 mg  I/ml or the 320 mg  I/ml formulation. Patients receiving non-
onic, monomeric LOCM were given iohexol 350 mg  I/ml (n = 601),
omeprol 350 mg  I/ml (n = 60), iopamidol 370 mg  I/ml (n = 630), or
opromide 370 mg  I/ml (n = 341). The remainder of the patients
iven LOCM were given the ionic dimer, ioxaglate 320 mg  I/ml
n = 1811).
uantitative synthesis of data
linical end points. Risk of total cardiovascular events
Data for within-hospital cardiovascular events were available
rom 12 studies (n = 6384 patients). The overall events rate was not
igniﬁcantly different between the 2 treatment groups: 162 cardio-
ascular events in the 3180 patients assigned to iodixanol (5.1%)
nd 213 cardiovascular events in the 3204 patients randomized to
OCM (6.6%), with a summary OR of 0.72 (95%CI 0.49–1.06, p = 0.09).
here was moderate heterogeneity across studies (I2 = 53; p = 0.01).Thirty-day cardiovascular events were recorded in 5 trials. A
otal of 135 events in the iodixanol arms (n = 2215) (6.1%) and 133
vents in the LOCM arms (n = 2260) (5.9%). This difference was not
tatistically signiﬁcant (OR = 1.19, 95%CI 0.70–2.02, p = 0.53). Thereerature search process.
was evidence of signiﬁcant statistical heterogeneity of trial results
(I2 = 64; p = 0.03).
The overall OR of cardiovascular events was not signiﬁcantly
decreased when iodixanol was compared with all LOCM pooled
together (OR = 0.86, 95%CI 0.63–1.16, p = 0.32) (Fig. 2).
Subgroup analysis
To explore potential heterogeneity, we  performed subgroup
analysis across several important study characteristics (Table 2).
A subgroup analysis limited to data speciﬁc for study design
demonstrated a reduction in within-hospital cardiovascular events
when iodixanol was  compared with LOCM in the RCTs sub-
group (OR = 0.65, 95%CI 0.44–0.96, p = 0.03) but not in the
non-randomized studies (OR = 2.68, 95%CI 0.15–47.52, p = 0.50).
A stratiﬁed analysis by the speciﬁc LOCM demonstrated no
relative difference in the risk of within-hospital cardiovascu-
lar events between iodixanol and ioxaglate (OR = 0.92, 95%CI
0.50–1.70, p = 0.80), or iohexol (OR = 0.75, 95%CI 0.48–1.17, p = 0.21)
(Table 2). In a subset analysis of the 10 studies involving 4490
patients in the setting of coronary angiography and percuta-
neous transluminal coronary angioplasty (PTCA), there was no
difference in within-hospital cardiovascular events risk between
patients randomized to iodixanol and LOCM (OR = 0.60, 95%CI
0.29–1.24, p = 0.17 for coronary angiography group and OR = 0.82,
95%CI 0.37–1.80, p = 0.62 for PTCA group, respectively) (Table 2).
Only 1 study used iomeprol, iopamidol, and iomeprol, respectively,
and hence no analysis could be performed.
Sensitivity analysis
A sensitivity analysis was  undertaken omitting one study ata time and calculating the pooled ORs for the remainder of the
studies. For in-hospital cardiovascular events, sensitivity analysis
showed that three studies [3,15,16] had a strong impact on the
association between iodixanol and LOCM (Table 3).
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Table  1
Characteristics of the studies included in the meta-analysis.
Andersen et al. (1993) [1] Hill et al. (1994) [12] Tveit et al. (1994) [13]
Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM
Patients (n) 36 38 101 99 53 49
Male  (%) 75 65.8 80.2 87.9 83.0 75.5
Mean  age (years) 54 56 61 ± 10 59 ± 11 58 58
Diabetes (%) NA NA NA NA NA NA
Mean  contrast
volume (ml)
107 106 103 ± 46 103 ± 37 135.4 139.3
Reason for contrast Cardiac angiography Cardiac angiography Cardiac angiography
Cardic adverse
events deﬁnition
Not speciﬁed Chest pain, ventricular ﬁbrillation Chest pain
In-hospital cardiac
events
2 6 2 3 3 6
30-Day cardiac
events
NA NA NA NA NA NA
Type  of LOCM Ioxaglate Iohexol Ioxaglate
Study design RCT RCT RCT
Location Norway U.S.A. Norway
Jadad score 3 2 2
Davidson et al. (2000) [7] Flinck et al. (2000) [14] Bertrand et al. (2000) [15]
Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM
Patients (n) 405 410 20 22 697 714
Male  (%) 69 66 75 86.4 78.2 76.2
Mean  age (years) 61 ± 12 62 ± 12 63 62 61.6 ± 10.6 62.3 ± 10.2
Diabetes (%) 27 27 NA NA 20.2 15.8
Mean  contrast volume (ml) 250 ± 114 285 ± 134 104 ± 19.6 101.5 ± 13.5 211.5 ± 99.3 228.0 ± 108.5
Reason  for contrast PTCA Cardioangiography PTCA
Cardiac adverse events deﬁnition Emergent recatheterization or
revascularization thromboembolic
event Cardiac death, Nonfatal MI
Emergent CABG, Stroke/TIA
Angina pectoris Death, stroke, Q-wave or
non-Q-wave MI,  CABG and/or
emergency re-PTCA
In-hospital cardiac events 22 39 2 33 28
30-Day cardiac events 15 15 NA NA 14 9
Type  of LOCM Ioxaglate Ioxaglate Ioxaglate
Study design RCT RCT RCT
Location U.S.A. Sweden European countries
Jadad  score 4 3 5
Flinck et al. (2001) [2] Sutton et al. (2002) [16] Harrison et al. (2003) [8]
Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM
Patients (n) 518 502 307 311 646 630
Male  (%) 72.6 70.3 64 73 NA NA
Mean  age
(years)
62.0 ± 11.3 61.4 ± 9.5 59.1 59.0 NA NA
Diabetes (%) NA NA 11 8.7 NA NA
Mean  contrast
volume (ml)
115 ± 44.8 113.5 ± 46.5 NA NA NA NA
Reason for
contrast
Cardioangiography PCI PCI
Cardic  adverse
events
deﬁnition
Angina pectoris, arrhythmia, dyspnea Cardiac death, emergency CABG,
MI, repeat PCI
Cardiac death, repeat PCI, CABG,
MI,  thrombosis
Stroke/TIA/embolus
In-hospital
cardiac events
36 45 18 13 31 57
30-Day cardiac
events
NA NA NA NA 79 89
Type  of LOCM Iohexol Ioxaglate Iopamidol
Study  design Prospective study RCT RCT
Location Sweden U.K. U.S.A.
Jadad  score 4 4
Le  Feuvre et al. (2006) [3] Schmid et al. (2007) [17] Nie et al. (2008) [18]
Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM
Patients (n) 231 267 60 60 106 102
Male  (%) 82 79 66.7 71.7 68.8 67.6
Mean  age (years) 64 ± 12 63 ± 11 60.6 ± 11.3 61.1 ± 9.9 61 ± 11.5 60 ± 12.3
Diabetes  (%) 28 34 NA NA 27.4 26.5
Mean  contrast
volume (ml)
267 ± 125 276 ± 120 NA NA 149.7 ± 100.6 158.2 ± 101.8
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Le Feuvre et al. (2006) [3] Schmid et al. (2007) [17] Nie et al. (2008) [18]
Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM
Reason for contrast Coronary angiography Cardiac angiography Coronary angiography
Cardiac adverse
events deﬁnition
Cardiac death, emergency CABG,
MI,  repeat PCI, stroke,
thromboembolic event
Ventricular extrasystoles Cardiac death, emergency CABG,
MI,  repeat PCI, stroke,
thromboembolic event
In-hospital cardiac
events
11 1 1 4 2 9
30-Day cardiac
events
14 2 NA NA NA NA
Type  of LOCM Ioxaglate Iomeprol Iopromide
Study design Prospective study RCT RCT
Location France Switzerland China
Jadad score 4 5
Bolognese et al. (2012) [9]
Iodixanol LOCM
Patients (n) 236 239
Male (%) 76 78
Mean age (years) 66 ± 12 65 ± 12
Diabetes (%) 20 21
Mean contrast volume (ml) 159 ± 74 156 ± 77
Reason for contrast PCI
Cardiac adverse events deﬁnition Cardiac death, reinfarction,
rehospitalization for heart failure
In-hospital cardiac events NA NA
30-Day cardiac events 13 18
Type of LOCM Iopromide
Study design RCT
Location European countries
Jadad score 4
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ypass grafting; PCI, percutaneous coronary intervention; MI,  myocardial infarction
eta-regression
With regard to in-hospital cardiovascular events risk between
odixanol and LOCM, REML estimate of the between-study variance
ith no covariates in the model was 0.1577. Univariate meta-
egression analyses were performed ﬁrst. Study size (12 studies,
 = 0.134), mean contrast volume (9 studies, p = 0.151), and age (10
tudies, p = 0.588) were assessed independently. These covariates
ailed to account for heterogeneity in any of the preplanned com-
arisons. Since we only found 5 studies for 30-day cardiovascular
vents, we were not able to perform meta-regression analysis.
umulative meta-analysis
A cumulative meta-analysis of a total of 12 studies was carried
ut to evaluate in-hospital cardiovascular events risk comparing
odixanol and LOCM in chronologic order. As shown in Fig. 3,
nclinations toward risk differences were not obvious over time.
imultaneously, the 95%CIs became increasingly narrower with
ccumulation of more data, suggesting the progressively improved
recision of the estimates by continually enlarging sample size.
ublication bias
The funnel plot did not show an asymmetric pattern (Fig. 4), and
oth Begg’s test and Egger’s test revealed no signiﬁcant publication
ias (Begg’s test, p = 0.115 and Egger’s test, p = 0.325 for in-hospital
ardiovascular events data. Begg’s test, p = 0.086 and Egger’s test,
 = 0.187 for 30-day cardiovascular events data).
iscussionThe main ﬁnding of this systematic review of the published
tudies and meta-analysis is that there is no signiﬁcant difference
n the incidence of in-hospital and 30-day cardiovascular events
hen using iodixanol than when using a pool of ionic and nonionicl; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery
 transient ischemic attack.
LOCM. A stratiﬁed analysis that directly compared the various
types of LOCM demonstrated that there is no relative difference in
within-hospital cardiovascular events when comparing iodixanol
with ioxaglate or iohexol. This suggests that the risk of cardic
events cannot be explained by osmolarity alone.
The lack of signiﬁcant difference in the incidence of within-
hospital cardiovascular events between those treated with
iodixanol and those treated with LOCM is also observed in patients
given coronary angiography or PTCA. Furthermore, cumulative
meta-analysis did not show a signiﬁcant change in trend of report-
ing risk of in-hospital cardiac events when comparing iodixanol
with LOCM between 1993 and 2008.
However, we  found a reduction in within-hospital cardiovascu-
lar events when iodixanol was compared with LOCM in the RCTs
subgroup (p = 0.03). In sensitivity analysis, after removing the stud-
ies by Le Feuvre et al. [3] Bertrand et al. [15], and Sutton et al. [16]
respectively, iodixanol seemed to decrease the in-hospital cardiac
events when compared with LOCM.
Contrast media are classiﬁed according to osmolarity, which
reﬂects the total particle concentration of the solution (the number
of molecules dissolved in a speciﬁc volume). Over the past 40 years,
the osmolarities of available contrast media have been gradually
decreased to physiological levels. In the 1980s, LOCM agents such as
iohexol, iopamidol, and ioxaglate were introduced. Although these
are classiﬁed as LOCM, their osmolarity is around 2–3 fold higher
than saline or IOCM [19]. In the 1990s, IOCMs with the same phys-
iologic osmolarity as blood were developed (e.g. iodixanol) [19].
Several experimental studies have demonstrated nonionic con-
trast media to have greater potential for thrombus formation,
thrombin generation, and platelet activation than ionic contrast
media [20,21], but all nonionic media may  not share the same
thrombogenic potential. The nonionic isosmolar dimer iodixanol
appears to have less thrombogenic potential and more favorable
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ffects on endothelial cells than the nonionic LOCM iohexol [22].
owever, iodixanol has been reported to increase platelet aggre-
ation, whereas ioxaglate inhibits it [23]. Similarly, prevention of
hrombin formation and platelet activation has been reported to be
chieved only with ioxaglate and not with iodixanol [24].
Previous clinical trials comparing iodixanol and LOCM in
atients undergoing cardiac angiography or intervention have
ielded conﬂicting results [3,7–9,12]. Some have shown the
able 2
ain analyses and sub-group analyses for the risk of total cardiovascular events between
Groups Studies (references) Cases 
All studies 13 [1–3,7–9,12–18] 6859 
In-hospital cardiovascular events 12 [1–3,7,8,12–18] 6384 
30-Day cardiovascular events 5 [3,7–9,15] 4475 
RCTs  subgroup 10 [1,7,8,12–18] 4866 
Prospective studies Subgroup 2 [2,3] 1518 
Iodixanol versus ioxaglate 7 [1,3,7,13–16] 3560 
Iodixanol versus Iohexol 2 [2,12] 1220 
Reason for contrast: coronary angiography 8 [1–3,12–14,17,18] 2264 
Reason for contrast: PTCA 2 [7,15] 2226 
OCM, low osmolar contrast media; RE, random effect; FE, ﬁxed effect; PTCA, percutaneoen iodixanol is compared with LOCM. LOCM, low-osmolar contrast media.
incidences of rethrombosis [3], and the lower cardiovascular event
rates associated with isosmolar iodixanol [7,8]. However, others
have demonstrated no difference in major ischemic complications
[9,12]. Our ﬁndings are consistent with those from a prospective
randomized trial comparing iodixanol and ioxaglate [15]. In that
study, no signiﬁcant difference in major adverse cardiac events
was observed. Overall events were low in both groups (4.7% for
iodixanol and 3.9% for ioxaglate).
 iodixanol and LOCM.
OR (95%CI) p value I2 (%) Pheterogeneity Model
0.86 (0.63–1.16) 0.32 57 0.002 RE
0.72 (0.49–1.06) 0.09 53 0.01 RE
1.19 (0.70–2.02) 0.53 64 0.03 RE
0.65 (0.44–0.96) 0.03 42 0.07 RE
2.68 (0.15–47.52) 0.50 87 0.006 RE
0.92 (0.50–1.70) 0.80 61 0.02 RE
0.75 (0.48–1.17) 0.21 0 0.87 FE
0.60 (0.29–1.24) 0.17 46 0.07 RE
0.82 (0.37–1.80) 0.62 77 0.04 RE
us transluminal coronary angioplasty.
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Table 3
Sensitivity analysis of in-hospital cardiovascular events between iodixanol and LOCM.
Included studies Excluded studies ORs (95%CI) p value I2 (%) Pheterogeneity
All studies None 0.72 (0.49–1.06) 0.09 53 0.01
[2–3,7–9,12–18] [1] 0.74 (0.50–1.11) 0.15 56 0.01
[1,3,7–9,12–18] [2] 0.70 (0.44–1.13) 0.14 58 0.009
[1–2,7–9,12–18] [3] 0.68 (0.49–0.94) 0.02 37 0.11
[1–3,8–9,12–18] [7] 0.75 (0.48–1.17) 0.20 55 0.01
[1–3,7,9,12–18] [8] 0.76 (0.49–1.18) 0.23 51 0.03
[1–3,7–9,12,14–18] [13] 0.74 (0.49–1.11) 0.14 57 0.01
[1–3,7–9,12–13,15–18] [14] 0.72 (0.48–1.08) 0.11 58 0.009
[1–3,7–9,12–14,16–18] [15] 0.65 (0.43–0.98) 0.04 47 0.04
[1–3,7–9,12–15,17–18] [16] 0.65 (0.44–0.98) 0.04 50 0.03
[1–3,7–9,12–16,18] [17] 0.74 (0.50–1.10) 0.13 56 0.01
[1–3,7–9,12–17] [18] 0.76 (0.52–1.12) 0.17 52 0.02
Andersen et al. (1993) [1]; Hill et al. (1994) [12]; Tveit et al. (1994) [13]; Davidson et al. (2000) [7]; Flinck et al. (2000) [14]; Bertrand et al. (2000) [15]; Flinck et al. (2001)
[2]; Sutton et al. (2002) [16]; Harrison et al. (2003) [8]; Le Feuvre et al. (2006) [3]; Schmid et al. (2007) [17]; Nie et al. (2008) [18].
Fig. 3. Forest plots of cumulative meta-analysis of the risk of in-hospital cardiovascular events when iodixanol is compared with LOCM. LOCM, low-osmolar contrast media.
Fig. 4. Funnel plot for publication bias in the studies investigating risk of cardiovascular events when iodixanol is compared with LOCM. (A) Funnel plot for in-hospital
cardiovascular events data. (B) Funnel plot for in-hospital cardiovascular events data. LOCM, low-osmolar contrast media.
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To the best of our knowledge, this is the ﬁrst meta-analysis to
stimate the risk of total cardiovascular events of the iso-osmolar
gent iodixanol and the currently available LOCM.
The current meta-analysis had some advantages. First, the num-
er of total participants and cardiovascular events were substantial,
hich signiﬁcantly increased the statistical power of the analy-
is. Second, the quantitative assessment was based on prospective
tudies and RCTs, which minimizes the possibility that our ﬁndings
esulted from recall or selection bias. Finally, there were no publi-
ation biases in these meta-analyses; therefore, the entire pooled
esult may  be unbiased.
Although this meta-analysis demonstrates that iodixanol is
ot superior to LOCM overall with regard to less cardiovascular
vents. Iso-osmolar contrast medium is better tolerated by patients
nd results in less marked hemodynamic and electrophysiologi-
al changes than does ioxaglate [25]. Also, beneﬁcial effects could
e obtained in patients with intraarterial administration and renal
nsufﬁciency, iodixanol is associated with a reduced risk of con-
rast medium-induced nephropathy (CIN) compared with iohexol
26]. Patients with CIN have more adverse cardiac outcomes than
atients without CIN [27]. In addition, the injection of iso-osmolar
ontrast medium did not inﬂuence capillary perfusion in patients
ith coronary artery disease [28] and the morphology of human
rterial and venous endothelial cells [29,30].
The possible limitations of our meta-analysis must be consid-
red. First, most studies only reported composite cardiovascular
ndpoints, since individual cardiovascular outcomes were unavail-
ble, and therefore we used aggregate data as reported in published
rticles (or as provided by their authors). Second, the included
tudies were different in terms of contrast media and deﬁnitions
f adverse cardiac events. Third, there is no consensus on how
ultivariable analyses should be conducted or reported in the
rimary studies. Thus, details on variables initially entered into
ultivariable models and those that ultimately were considered
igniﬁcant predictors were often incomplete. This limits the ability
o perform meta-analytic pooling of risk factors. In addition, many
tudies included here reported limited details, and for several oth-
rs, we combined the occurrence of clinical cardiovascular events
s a single endpoint to increase statistical power. Accordingly, no
dditional details beyond those reported could be extracted from
hem. Fourth, this meta-analysis consists mainly of the RCTs stud-
es, which may  inﬂuence our results.
onclusions
In conclusion, the ﬁndings of this meta-analysis suggested that
here appears to be no difference in the risk of total cardiovascular
vents when iodixanol is compared with LOCM.
But these results are not robust and inconclusive after con-
ucting the sensitivity analysis and RCTs subgroup analysis. More
tudies, especially RCTs, are needed to conﬁrm this association.
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